Intervention
Pidnarulex
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
2 shownTesting the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · 2026-10-05
RECRUITINGPidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerNCT05425862 · 2022-10-21
SUSPENDEDCommon conditions
Anatomic Stage III Breast Cancer AJCC v81Anatomic Stage IV Breast Cancer AJCC v81Invasive Breast Carcinoma1Locally Advanced Breast Carcinoma1Metastatic Breast Carcinoma1Metastatic Castration Resistant Prostate Cancer (mCRPC)1Metastatic HER2-Low Breast Carcinoma1Metastatic HER2-Positive Breast Carcinoma1Metastatic Hormone Receptor-Positive Breast Carcinoma1Metastatic Malignant Solid Neoplasm1Metastatic Triple-Negative Breast Carcinoma1Unresectable Breast Carcinoma1Unresectable HER2-Low Breast Carcinoma1Unresectable HER2-Positive Breast Carcinoma1Unresectable Hormone Receptor-Positive Breast Carcinoma1Unresectable Malignant Solid Neoplasm1Unresectable Triple-Negative Breast Carcinoma1
Leading sponsors
Trial status mix
RECRUITING1
SUSPENDED1
Phase mix
PHASE12
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.